UNICREDIT BANK/CALL/ELI LILLY & CO/1150/0.1/17.06.26 Share Price

Warrant

DE000HD4LBP2

Real-time BOERSE MUENCHEN 12:40:01 23/05/2024 BST
7 EUR 0.00% Intraday chart for UNICREDIT BANK/CALL/ELI LILLY & CO/1150/0.1/17.06.26
Current month+5.58%
1 month+28.91%
Date Price Change
23/05/24 7 0.00%
22/05/24 7 -0.14%
21/05/24 7.01 +12.88%
20/05/24 6.21 +4.37%
17/05/24 5.95 -2.94%

Real-time BOERSE MUENCHEN

Last update May 23, 2024 at 12:40 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELI LILLY AND COMPANY
IssuerLogo Issuer UniCredit UniCredit
WKN HD4LBP
ISINDE000HD4LBP2
Date issued 12/04/2024
Strike 1,150 $
Maturity 17/06/2026 (756 Days)
Parity 10 : 1
Emission price 6.77
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 7.1
Lowest since issue 5.07
Delta0.37x
Omega 3.838
Premium52.85x
Gearing10.4x
Moneyness 0.6982
Difference Strike 347.1 $
Difference Strike %+30.18%
Spread 0.52
Spread %7.05%
Theoretical value 7.120
Implied Volatility 33.53 %
Total Loss Probability 78.94 %
Intrinsic value 0.000000
Present value 7.120
Break even 1,227.21 €
Theta-0.08x
Vega0.4x
Rho0.42x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9 USD
Average target price
850.4 USD
Spread / Average Target
+5.92%
Consensus